Cargando…

Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer

BACKGROUND: Disease recurrence and progression of ovarian cancer is a common event, which is accompanied by the development of platinum-resistant or refractory disease. The presence of chemo-resistant Cancer Stem Cells (CSCs) contribute to tumor propagation, maintenance, and treatment resistance of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howard, Candace M, Bush, Stephen, Zgheib, Nadim Bou, Lirette, Seth T, Cortese, Antonio, Mollo, Antonio, Valluri, Jagan, Claudio, Pier Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597976/ https://www.ncbi.nlm.nih.gov/pubmed/34796266 http://dx.doi.org/10.24966/srdt-2060/100076

Ejemplares similares

Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer()
por: Howard, Candace M., et al.
Publicado: (2020)

Treatment of unmethylated MGMT-promoter recurrent glioblastoma with cancer stem cell assay-guided chemotherapy and the impact on patients’ healthcare costs
por: Ranjan, Tulika, et al.
Publicado: (2023)

Cancer Stem Cell Chemotherapeutics Assay for Prospective Treatment of Recurrent Glioblastoma and Progressive Anaplastic Glioma: A Single-Institution Case Series()
por: Ranjan, Tulika, et al.
Publicado: (2020)

Analysis of Chemopredictive Assay for Targeting Cancer Stem Cells in Glioblastoma Patients
por: Howard, Candace M., et al.
Publicado: (2017)

A new complementary procedure for patients affected by head and neck cancer: Chemo-predictive assay
por: Cortese, Antonio, et al.
Publicado: (2016)

Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial
por: Ranjan, Tulika, et al.
Publicado: (2023)

Endometriosis and ovarian cancer risk, an epigenetic connection
por: Brunty, Sarah, et al.
Publicado: (2020)

Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer
por: Brunty, Sarah, et al.
Publicado: (2021)

SYST-01 MULTI-INSTITUTIONAL RANDOMIZED TRIAL COMPARING CANCER STEM CELL-TARGETED VS PHYSICIAN-CHOICE TREATMENTS IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS (NCT03632135)
por: Sengupta, Soma, et al.
Publicado: (2022)

Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer
por: Koc, Zeynep C., et al.
Publicado: (2023)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Rapid Selection and Proliferation of CD133(+) Cells from Cancer Cell Lines: Chemotherapeutic Implications
por: Kelly, Sarah E., et al.
Publicado: (2010)

Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
por: López-Guerrero, José Antonio, et al.
Publicado: (2015)

Recurrent Neuroendocrine Tumor of the Cervix Presenting With Ectopic Cushing’s Syndrome
por: Rico, Jeffrey G, et al.
Publicado: (2022)

Epi-Mucosa Fixation and Autologous Platelet-Rich Fibrin Treatment in Medication-Related Osteonecrosis of the Jaw
por: Cortese, Antonio, et al.
Publicado: (2021)

Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment
por: Chien, Jeremy, et al.
Publicado: (2013)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
por: Guerra Alía, Eva María, et al.
Publicado: (2019)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review
por: Conte, Carmine, et al.
Publicado: (2021)

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
por: Mantia-Smaldone, Gina M, et al.
Publicado: (2010)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
por: Ball, Graeme, et al.
Publicado: (2017)

Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer
por: Sinsuwan, Woraporn, et al.
Publicado: (2023)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer
por: Le, Tran N., et al.
Publicado: (2017)

Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report
por: Sun, Li, et al.
Publicado: (2020)

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
por: Pan, Zhongmian, et al.
Publicado: (2023)

Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
por: Zou, Ruoyao, et al.
Publicado: (2023)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Chemo-Predictive Assay for Targeting Cancer Stem-Like Cells in Patients Affected by Brain Tumors
por: Mathis, Sarah E., et al.
Publicado: (2014)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
por: Cottrill, Hope, et al.
Publicado: (2018)

Platelet-Rich Fibrin (PRF) in Implants Dentistry in Combination with New Bone Regenerative Flapless Technique: Evolution of the Technique and Final Results
por: Cortese, Antonio, et al.
Publicado: (2017)

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
por: Lee, C K, et al.
Publicado: (2011)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
por: Pejovic, Tanja, et al.
Publicado: (2022)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2015)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Exosomes as mediators of platinum resistance in ovarian cancer
por: Crow, Jennifer, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_51kp7f1l8r2o2tddhk85bjooet